Trials / Completed
CompletedNCT04571385
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study of AP30663 Given Intravenously for Cardioversion in Patients With Atrial Fibrillation
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Acesion Pharma · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of one or more doses of AP30663 for cardioversion in adult participants with AF.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AP30663 | Administer by intravenous infusion. |
| DRUG | Placebo | Placebo matched to AP30663. |
Timeline
- Start date
- 2019-09-09
- Primary completion
- 2022-12-13
- Completion
- 2023-01-23
- First posted
- 2020-10-01
- Last updated
- 2024-05-06
- Results posted
- 2024-05-06
Locations
15 sites across 2 countries: Denmark, Hungary
Source: ClinicalTrials.gov record NCT04571385. Inclusion in this directory is not an endorsement.